📰 Trevena News
Page 5 - Trevena News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Trevena. Real-time updates on events, politics, business and more.
April 14, 2023
Trevena, Inc. (NASDAQ:TRVN – Get Rating) saw a large drop in short interest in March. As of March 31st, there was short interest totalling 53,400 shares, a drop of 57.2% from the March 15th total of 124,900 shares. Based on an average daily trading volume, of 104,200 shares, the short-interest ratio is currently 0.5 days. […]
April 8, 2023
StockNews.com upgraded shares of Trevena (NASDAQ:TRVN – Get Rating) to a sell rating in a research report sent to investors on Tuesday morning. Several other brokerages have also issued reports on TRVN. HC Wainwright decreased their price target on shares of Trevena from $11.00 to $9.00 and set a buy rating for the company in […]
April 5, 2023
Trevena (NASDAQ:TRVN – Get Rating) was upgraded by research analysts at StockNews.com to a “sell” rating in a report released on Tuesday. Other equities analysts also recently issued reports about the company. JMP Securities restated a “market outperform” rating and set a $2.00 price objective on shares of Trevena in a research report on Friday. […]
April 4, 2023
JMP Securities reaffirmed their market outperform rating on shares of Trevena (NASDAQ:TRVN – Get Rating) in a report published on Friday morning, Benzinga reports. JMP Securities currently has a $2.00 target price on the biopharmaceutical company’s stock. Other equities research analysts have also recently issued research reports about the stock. StockNews.com began coverage on shares […]
April 4, 2023
Trevena (NASDAQ:TRVN – Get Rating) and Merck & Co., Inc. (NYSE:MRK – Get Rating) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk and profitability. Insider and Institutional Ownership 72.9% of Merck & Co., […]
March 30, 2023
Trevena (NASDAQ:TRVN – Get Rating) and Merck & Co., Inc. (NYSE:MRK – Get Rating) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation. Analyst Ratings This is a summary of current ratings […]
March 29, 2023
Trevena (NASDAQ:TRVN – Get Rating) will issue its quarterly earnings data before the market opens on Thursday, March 30th. Parties interested in registering for the company’s conference call can do so using this link. Trevena Price Performance NASDAQ:TRVN opened at $0.75 on Wednesday. Trevena has a one year low of $0.65 and a one year […]
May 16, 2022
Trevena, Inc. (NASDAQ:TRVN – Get Rating) – Research analysts at Oppenheimer raised their FY2022 earnings per share estimates for Trevena in a note issued to investors on Wednesday, May 11th. Oppenheimer analyst J. Jones now expects that the biopharmaceutical company will earn ($0.30) per share for the year, up from their previous estimate of ($0.39). […]
March 31, 2022
CHESTERBROOK, Pa., March 31, 2022 -- Trevena, Inc. , a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system ... | March 31, 2022
March 17, 2022
Trevena, Inc. (NASDAQ:TRVN – Get Rating) was the target of a large decline in short interest in February. As of February 28th, there was short interest totalling 3,600,000 shares, a decline of 20.9% from the February 13th total of 4,550,000 shares. Currently, 2.3% of the shares of the stock are short sold. Based on an […]